POLYMORPHISM/ GENOTYPE/ ALLELE | CAD PATIENTS (n = 400) (%) | CONTROLS (n = 400) (%) | OR (95% CI) | Adjusted p-value |
---|---|---|---|---|
5-HTTLPR SS SL LL S L χ2 | 210 (52.5%) 150 (37.5%) 40 (10%) 0.7 0.3 2.86 (p = 0.1) | 245 (61.25%) 130 (32.5%) 25 (6.25%) 0.77 0.23 1.85 (p = 0.2) | 1 (Ref.) 1.35 (1.0-1.81) 1.87 (1.10–3.18) 1 (Ref.) 1.39 (1.11–1.74) | 0.05 0.03* 0.01* |
rs25531 S’ S’ S’LA LALA S’ LA χ2 | 276 (69%) 107 (26.75%) 17 (4.25%) 0.82 0.18 2.48 (p = 0.11) | 288 (72%) 97 (24.25%) 15 (3.75%) 0.84 0.16 3.39(p = 0.06) | 1 (Ref.) 1.15 (0.83–1.59) 1.18 (0.58–2.41) 1(Ref.) 1.13 (0.87–1.47) | 0.6 0.64 0.9 |
VNTR STin2 12/12 rpts 12/10 rpts 10/10 rpts 12 rpt 10 rpt χ2 | 190 (47.5%) 171 (42.75%) 39 (9.75%) 0.69 0.31 0.50 (p = 0.47) | 180 (45%) 167 (41.75%) 53 (13.25%) 0.66 0.34 2.04 (p = 0.15) | 1 (Ref.) 0.97 (0.72–1.03) 0.70 (0.44–1.11) 1 (Ref.) 0.87 (0.71–1.07) | 0.8 0.3 0.3 |